Good day, and welcome to the Spring Bank Pharmaceuticals Second Quarter 2018 Corporate Update Conference Call. At this time, I would like to turn the conference over to Marty Driscoll, CEO of Lifestyle Advisers. Please go ahead, sir.
Martin Driscoll
Good morning, everyone, and welcome to the Spring Bank Corporate Update Call. Just as a correction, I'm actually the CEO of Spring Bank Pharmaceuticals. This is Marty Driscoll, and I'm happy to be chatting with everyone this morning. Joining me this morning on the call is Dr. Ned Afdhal, the Chief Medical Officer at Spring Bank.
I think many of you that know us know that, typically John Freve, our Chief Financial Officer, joins us on these calls. John has experienced a death in his family and won't be joining us this morning.
Before we begin our discussion of the update, let me show you our forward-looking statement. Before we begin this presentation, allow me the opportunity to mention that, in today's call, we will be making forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements.
Additional information regarding these factors is discussed under the forward-looking statements section in the press release we issued this morning as well as in Spring Bank's SEC filings. Forward-looking statements during this call speak only as of the original date of this call, and we undertake no obligation to update or revise any of these statements.
Ladies and gentlemen, this morning on this call we're excited to present to you a summary of the compelling data that we have generated for our oral immunomodulator, inarigivir. This is from Part A of the ongoing Phase II trial in chronic HBV patients. Specifically, Dr. Afdhal, in a few minutes will detail the positive results from Cohort 3 of the inarigivir dose escalation ACHIEVE trial. I hope all of you saw the press release that we issued this morning just about an hour to an house and half ago.
As you are likely aware, Cohort 3 of our ACHIEVE trial involved the administration of inarigivir 100 milligrams once daily for 12 weeks followed by tenofovir disoproxil fumarate or as we all know it Viread, once daily for another 12 weeks. We are excited by the results from inarigivir from this 100-milligram cohort because the data continue to demonstrate an excellent dose response on the key anabolic parameters for chronic HBV.
It's this Cohort 3 data reveals that inarigivir continues to demonstrate impressive dose-dependent responses on both HBV DNA and HBV RNA. The data also continues to reveal to us that inarigivir is the only oral treatment in the HBV development space that has demonstrated a clinically meaningful effect on hepatitis B surface antigen. For the three ACHIEVE cohorts combined the inarigivir treatment arms have demonstrated a predefined surface antigen response in 28% of patients with a mean reduction of almost one log.
As you read the press release and as we've announced this morning, we are also pleased to report to you that our partners at Gilead are significantly expanding the clinical work they are conducting with inarigivir in HBV. Gilead is adding two cohorts to their ongoing inarigivir 50-milligram plus Vemlidy clinical trial to include new cohorts involving the administration of 200-milligrams of inarigivir plus Vemlidy in naïve HBV patients and 100 milligrams of inarigivir in Nuc-suppressed HBV patients.作者: newchinabok 时间: 2018-8-6 18:10